Tarsons Products Ltd (TARSONS) — FY26 Annual Report | 2 September 2026 (2 announcements)

Tarsons Products Ltd reported FY2025-26 revenue of ₹3,329.31 million, up from ₹3,141.77 million, with PAT margin declining to 6.81% (from 13.60%) due to investments in new facilities. EBITDA margin stood at 32.73%, and PAT was [amount context mismatch] million. The company expanded manufacturing at Panchla and Amta, commissioned a sterilization unit in August 2025, and acquired Nerbe to strengthen European presence. It targets 120 export countries over 5-10 years, with 40+ countries currently served. CSR spending reached ₹15.75 million for Tata Medical Centre Trust. No dividends were declared.

Tarsons Products Limited informed shareholders via a regulatory letter that the FY 2025-26 Annual Report and 43rd AGM notice are accessible on its website at www.tarsons.com/financial-reports/ and www.tarsons.com/disclosure/ for accessing the AGM details and financial disclosures.